Kymera Therapeutics, Inc. (KYMR)
KYMR Stock Price Chart
Explore Kymera Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze KYMR price movements and trends.
KYMR Company Profile
Discover essential business fundamentals and corporate details for Kymera Therapeutics, Inc. (KYMR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Aug 2020
Employees
208.00
Website
https://www.kymeratx.comCEO
Nello Mainolfi
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR Financial Timeline
Browse a chronological timeline of Kymera Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.73.
Earnings released on 11 Aug 2025
EPS came in at -$0.95 falling short of the estimated -$0.83 by -14.46%, while revenue for the quarter reached $11.48M , missing expectations by -33.01%.
Earnings released on 9 May 2025
EPS came in at -$0.82 surpassing the estimated -$0.92 by +10.87%, while revenue for the quarter reached $22.10M , beating expectations by +78.49%.
Earnings released on 27 Feb 2025
EPS came in at -$0.88 falling short of the estimated -$0.76 by -15.79%, while revenue for the quarter reached $7.39M , missing expectations by -55.67%.
Earnings released on 31 Oct 2024
EPS came in at -$0.82 surpassing the estimated -$0.83 by +1.20%, while revenue for the quarter reached $3.74M , missing expectations by -75.41%.
Earnings released on 7 Aug 2024
EPS came in at -$0.58 surpassing the estimated -$0.69 by +15.94%, while revenue for the quarter reached $25.65M , beating expectations by +104.38%.
Earnings released on 2 May 2024
EPS came in at -$0.69 surpassing the estimated -$0.73 by +5.48%, while revenue for the quarter reached $10.29M , missing expectations by -24.86%.
Earnings released on 22 Feb 2024
EPS came in at -$0.25 surpassing the estimated -$0.44 by +43.18%, while revenue for the quarter reached $47.89M , beating expectations by +14.12%.
Earnings released on 2 Nov 2023
EPS came in at -$0.90 falling short of the estimated -$0.73 by -23.29%, while revenue for the quarter reached $4.73M , missing expectations by -70.39%.
Earnings released on 3 Aug 2023
EPS came in at -$0.67 surpassing the estimated -$0.70 by +4.29%, while revenue for the quarter reached $16.51M , beating expectations by +17.45%.
Earnings released on 4 May 2023
EPS came in at -$0.70 falling short of the estimated -$0.69 by -1.45%, while revenue for the quarter reached $9.47M , missing expectations by -33.10%.
Earnings released on 23 Feb 2023
EPS came in at -$0.60 falling short of the estimated -$0.57 by -5.26%, while revenue for the quarter reached $16.14M , missing expectations by -26.82%.
Earnings released on 3 Nov 2022
EPS came in at -$0.79 falling short of the estimated -$0.70 by -12.86%, while revenue for the quarter reached $9.55M , missing expectations by -38.43%.
Earnings released on 9 Aug 2022
EPS came in at -$0.78 falling short of the estimated -$0.68 by -14.71%, while revenue for the quarter reached $11.51M , missing expectations by -19.13%.
Earnings released on 3 May 2022
EPS came in at -$0.71 falling short of the estimated -$0.67 by -5.97%, while revenue for the quarter reached $9.62M , missing expectations by -48.67%.
Earnings released on 24 Feb 2022
EPS came in at -$0.66 falling short of the estimated -$0.36 by -83.33%, while revenue for the quarter reached $15.28M , missing expectations by -28.33%.
Earnings released on 10 Nov 2021
EPS came in at -$0.56 falling short of the estimated -$0.34 by -64.71%, while revenue for the quarter reached $20.34M , beating expectations by +14.48%.
Earnings released on 6 Aug 2021
EPS came in at -$0.55 falling short of the estimated -$0.21 by -161.90%, while revenue for the quarter reached $18.52M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$0.29 falling short of the estimated -$0.17 by -70.59%, while revenue for the quarter reached $18.70M , beating expectations by +19.72%.
Earnings released on 11 Mar 2021
EPS came in at -$0.29 falling short of the estimated $0.09 by -422.22%, while revenue for the quarter reached $12.79M .
Earnings released on 5 Nov 2020
EPS came in at -$0.39 falling short of the estimated -$0.21 by -85.71%, while revenue for the quarter reached $14.53M , beating expectations by +25.70%.
KYMR Stock Performance
Access detailed KYMR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.